Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 3Phase NA 1Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Genitourinary 2Gynecologic 1CNS 1

Conditions

Spinal Cord Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 11Lomustine 6Radiotherapy 4Magnetic Resonance Spectroscopy 3Etoposide 3Carboplatin 3Bevacizumab 3vocimagene amiretrorepvec 2Vincristine 2Radiation 2Gefitinib 2veliparib 1trofosfamide 1trametinib 1tozuleristide 1tinostamustine 1regorafenib 1omburtamab I-131 1entrectinib 1dabrafenib 1cobimetinib 1carbon-11 acetate 1capmatinib 1antisecretory factor 1alectinib 1Vorinostat 1Vemurafenib 1Thiotepa 1Sunitinib 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Disulfides × CNS × Clear all
NCT01236560 2024-02-20

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

National Cancer Institute (NCI)

Phase 2/3 Completed
101 enrolled 15 charts
CNS

Astrocytoma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡